Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
This gene silencing by ubiquitinated histone is vital in normal embryo development, and it goes awry in some cancers.
UAB researchers want to create new treatments for these banes of cardiovascular disease.
Researchers have discovered the mechanism of this control, with implications for developmental biology, the immune response and cancer dysregulation.
Early exposure to science, technology and medicine is the start of a path to STEM careers.
The inhibitor blocks Streptococcus mutans from sticking on the tooth surface. About 2.3 billion people worldwide have tooth decay in their permanent teeth, primarily caused by this bacteria.
An enthusiastic teacher and a fascinating topic lit his desire to learn. Now the veteran is building bone scaffolding with a three-dimensional bioprinter.
The August issue of the journal focused on genomics in rheumatic diseases, the complex effort to understand the genetic underpinnings of more than 100 diseases that affect joints and muscles.
Undergraduate research opportunity attracts students from across the United States.
Improvements in motor function and memory suggest human neurodevelopmental disorders may be amenable to treatment, even after onset of symptoms. According to a researcher, neurodevelopmental disorders with intellectual disability and autism may not need to last a lifetime.
This potential chemotherapeutic agent to treat glioblastoma — a primary brain tumor with dismal survival rates — is a novel small molecule inhibitor.